Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T-cell lymphoma

Robert Stuver, Steven M. Horwitz, Ranjana H. Advani, Julie M. Vose, Hun Ju Lee, Neha Mehta-Shah, Jasmine M. Zain, Bradley Haverkos, Mary Jo Lechowicz, Alison J. Moskowitz, Luu Q. Pham, Elizabeth Leyden, Stephen M. Ansell, Matthew A. Lunning

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

There remains no one standard induction for nodal-based peripheral T-cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1–10 of a 21-day cycle for six cycles of therapy followed by observation, high-dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty-two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2-year progression-free and overall survival were 55% (95% CI 37%–70%) and 78% (95% CI 59%–89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction.

Original languageEnglish (US)
Pages (from-to)525-529
Number of pages5
JournalBritish Journal of Haematology
Volume202
Issue number3
DOIs
StatePublished - Aug 2023

Keywords

  • T-cell lymphoma
  • clinical trials
  • lymphomas
  • malignant lymphomas
  • non-Hodgkins lymphoma
  • trials

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Cite this